To ultimately save lives by accelerating the development and deployment of needed diagnostics, the Wyss Diagnostics Accelerator (DxA) formed as a multifaceted collaboration between clinicians, researchers, engineers, funding agencies, philanthropists, government agencies, and industry partners. These partners work together to:
- Identify unmet diagnostic needs
- Fund technology research and development
- Conduct clinical studies
- Work with regulators, payers, NGOs, and industry to advance commercialization efforts of the most promising technologies
- Ultimately measure successful outcomes in all settings, particularly with underserved populations
Bench to Bedside: Clinical Collaboration
Our acceleration process begins with clinicians who identify critical unmet medical diagnostic needs. They then work alongside Wyss scientists and engineers to help develop technologies to address these specific problems. As promising technologies are developed in Wyss labs, they are brought to the CLIA-certified lab at the Brigham and Women’s Hospital (BWH) to be tested with real patient samples. The CLIA designation is granted by the FDA and sets clinical standards for clinical laboratory testing performed on human samples, which means these Wyss-developed technologies are being used under similar standards that the FDA uses when evaluating products for approval in the market. The Wyss teams then use clinician feedback to further refine and enhance these technologies before bringing them back to the CLIA lab.
Members of the BWH community can use our online portal to submit information about unmet clinical needs where a novel or improved diagnostic or prognostic test will enhance the quality or efficiency of clinical care and patient outcomes. We consider all patient populations, disease states and testing modalities.
Industrial Participant Program
Developing a new diagnostic that tests well in the lab is not enough – these tools need to work well at scale and in the market. The Wyss DxA Industrial Participant Program (IPP) serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem.
Participants build relationships and explore pre-competitive collaboration opportunities, connect with thought leaders and subject matter experts, identify key opportunities and challenges within the industry, and align on a vision to transform the future of diagnostic and healthcare testing, all driven by the passion to solve unmet diagnostic needs.
We are currently seeking new members to join the pilot phase of our Industrial Participant Program, which launches in Fall 2021. Please get in touch with the Wyss Diagnostics Accelerator Program Lead Rushdy Ahmad to learn more.